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1. Introduction 
Sigma (σ) receptors represent a class of proteins that were initially classified as a subtype of 
the opiate receptors. Subsequent studies revealed that σ binding sites are a distinct class of 
receptors that are located in the central nervous system as well as in a variety of tissues and 
organs [1, 2]. Two σ binding site subtypes were distinguished based on differences in their 
drug-binding profiles and molecular weight. The two binding sites are known as σ1 and σ2 
receptors. σ1 receptors have a molecular weight of ~25 kDa, whereas σ2 receptors have a 
molecular weight of ~21.5 kDa [3]. The σ1 receptor has been cloned and displays a 30% 
sequence homology with the enzyme, yeast C8-C7 sterol isomerase [4, 5], but this receptor 
lacks C8-C7 isomerase activity. Recent studies have shown that neuroactive steroids bind 
with moderate affinity to σ1 sites, and suggest that σ1 receptors may modulate the activity of 
GABA and NMDA receptors in the CNS [6-8]. The σ2 receptor has not been cloned, and 
most of what is known regarding the σ2 receptor has been obtained through the use of in 
vitro receptor binding studies aimed at the pharmacological characterization of this 
receptor. 
2. Characterization of the σ2 receptor as a biomarker of the proliferative 
status of solid tumors 
The first report suggesting that there is an overexpression of σ receptors in tumors cells was 
by Bem et al. in 1991[9]. In this study, σ binding in tumors was found to be greater than or 
equal to 2-fold higher than that of control nonmalignant tissue. Later, Vilner et al.[10] 
demonstrated that many murine and human tumor cells possess a high density of σ2 
receptors when grown under cell culture conditions. These studies clearly indicate that σ2 
receptors may serve as a biomarker for differentiating solid tumors from the surrounding 
normal tissues. The proliferative status of a solid tumor, which is defined as the ratio of 
proliferating (P) cells in a solid tumor to those driven into a quiescent (Q) state by nutrient 
deprivation and/or hypoxia (the P:Q ratio), is an important parameter in determining how 
to treat a tumor with either radiation or chemotherapy[11]. Tumors having a high 
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proliferative status (i.e., high P:Q ratio) typically respond better to hyperfractionated 
radiation therapy versus conventional radiation therapy. Similarly, tumors having a high 
P:Q ratio will respond better to cell cycle specific agents such as Ara-C and gemcitabine, 
whereas tumors having a lower proliferative status will respond better to non-cell cycle 
specific agents such as cisplatin and BCNU [11]. Also, a change in the proliferative status of 
a tumor during or after treatment has the potential to serve as a predictor of response and 
allow further tailoring of therapy. 
In order to investigate the relationship between the density of σ2 receptors and the 
proliferative status of tumors, Wheeler and colleagues used the mouse mammary 
adenocarcinoma cell line 66[12, 13] to determine if there was a difference in the density of σ2 
receptors in proliferating (66P) and quiescent (66Q) tumor cells in cell culture or in solid 
tumor xenografts. This group demonstrated that the density of σ2 receptors in 66P cells was 
about 10 times greater than the density observed in 66Q cells (Figure 1A)[14]. The density of 
σ2 receptors in the 66P cells was found to be quite high, ~900,000 copies/cell versus ~90,000 
receptors/cell in the 66Q cells. This group also reported that the expression kinetics of σ2 
receptors follows the growth kinetics of the 66 cells (Figure 1B)[15]. A subsequent study in 
solid tumor xenografts of the same tumor cell lines demonstrated the identical P:Q ratio to 
that measured in the cell culture condition[16]. The agreement between the solid tumor and 
tissue culture data indicates that the σ2 receptor is a receptor-based biomarker of cell 
proliferation in breast tumors. Thus the 2 receptor possesses properties similar to Ki-67, a 
marker of proliferation [17]. Ki-67 expression level is determined by immunohistochemistry 
using Ki-67 antibody. This method requires biopsy or surgical specimens of tumor. In 
contrast, radiotracers having a high affinity and high selectivity for σ2 receptors have the 
potential to assess the proliferative status of human breast tumors using noninvasive 
imaging techniques such as Positron Emission Tomography (PET) and Single Photon 
Emission Computed Tomography (SPECT). In addition, it is likely that this approach can be 
extended to assess the proliferative status of other human tumors, such as head and neck, 
melanoma, and lung tumors, which are known to express a high density of σ2 receptors[10]. 
Imaging the proliferative status with σ2 receptors radiotracers can provide useful 
information regarding the prognosis and aggressiveness of tumors, and this information can 
be used to guide treatment of cancer in clinical practice. Rapidly proliferating tumors 
requires aggressive initial treatment. A reduction in the proliferative status of a tumor can 
serve as a predictor of the tumor’s response to therapy.  
3. Development of σ2 receptor selective ligands 
A number of structurally-diverse compounds have been shown to possess a high affinity to 
σ receptors [2]. However, most of these compounds bind selectively to σ1 receptor or have 
similar affinities to both σ1 and σ2 receptors. One of the first σ2 selective ligands reported was 
the benzomorphan-7-one analog, CB-64D [18]. This compound was identified as part of a 
structure-activity relationship (SAR) study aimed at refining the affinity of (−)-2-methyl-5-
(3-hydroxyphenyl)morphan-7-one for μ versus κ opioid receptors [19]. A second series of 
compounds having a high affinity for σ2 receptors are the 3-(ω-aminoalkyl)-1H-indole 
analogs [20, 21]. SAR studies with compounds that were originally designed to be serotonin 
5-HT1A agonists, resulted in the synthesis of Lu 28-179 [22], also known as siramesine， 
which has a subnanomolar affinity for σ2 receptors and a 140-fold selectivity for σ2 versus σ1 
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receptors. Other compounds that were found to have a higher affinity for σ2 versus σ1 
receptors are: 1) the hallucinogen, ibogaine [23, 24]; 2) the mixed serotonin 5-HT3 
antagonist/5-HT4 agonist BIMU-1[25]; 3) the tropane analog SM-21, an acetylcholine 
releaser that has been utilized as an antinociceptic agent [26, 27]; 4) the trishomocubane 
analog ANSTO-19 [28]; and 5) the piperazine analog PB28 [29].  
 
 
Fig. 1. The 2 receptor densities in proliferating and quiescent cells. A: Differences of the 2 
receptor densities in 66P and 66Q cells. B: The 2 receptor expression kinetics in 66 cells 
during the Q to P transition and the downregulation of the 2 receptor densities during the 
P to Q transition. 
A number of SAR studies using BIMU-1 as the lead compound have identified high affinity, 
high selectivity σ2 receptor ligands [30-32]. BIMU-1 is an ideal lead compound for SAR 
studies since it provides a variety of regions where structural modifications can be made to 
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optimize the σ2 receptor affinity and reduce the affinity for serotonin 5-HT3 and 5-HT4 
receptors (Figure 2). The structures of BIMU-1 were altered in three different regions: 1) 
replacement of the urea linkage with a comformationally-flexible carbamate moiety; 2) 
replacement of the N-methyl group with an N-benzyl group to diminish serotonin receptor 
affinity; and 3) preparation of both tropane (i.e., [3.2.1]azabicyclonoctane) and granatane 
(i.e., [3.3.1]azabicyclononane) ring systems. The most interesting analog from this initial 
SAR study was the compound ABN-1, which had a σ2 receptor affinity of ~ 3 nM and a σ2: σ1 
selectivity of ~30 (Figure 2)[31]. Compound ABN-1 was used as a secondary lead compound 
for a series of subsequent SAR studies aimed at producing second-generation granatane 
analogs having an improved σ2 receptor affinity and high σ2: σ1 selectivity ratio. 
Consequently, this led to the development of a number of fluorescent probes, K05-138, 
SW120, SW107 and SW116, that have proven useful in two photon and confocal microscopy 
studies of σ2 receptors in tumor cells growing under cell culture conditions[33, 34].  
 
 
Fig. 2. Structures of BIMU-1 and the granatane analogs. ABN-1 was used as a lead for 
producing second-generation granatane-based σ2 receptor ligands, which led to the 
development of a number of fluorescent probes, K05-138, SW120, SW107 and SW116, for 
two photon and confocal microscopy studies of σ2 receptors in tumor cells.  
A second class of compounds having a high affinity for σ2 receptors and excellent σ1 : σ2 
selectivity ratios are the conformationally-flexible benzamide analogs. These compounds 
were identified in an SAR study of the benzamide analog, YUN250, that was developed as a 
dopamine D3-selective ligand (Figure 3A) [35]. The relatively high lipophilicity of YUN250 
(log P = 5.76) suggests that it is not capable of readily crossing the blood-brain barrier and 
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being active in behavioral studies. In order to reduce the lipophilicity of YUN250, the 4-(2,3-
dichlorophenyl) piperazine moiety of YUN250 was replaced with other aromatic amine 
groups. Although this strategy resulted in a number of useful dopamine D3 receptor ligands 
[36], it was also observed that replacement of the 4-phenylpiperazine moiety with a 6,7-
dimethoxy-1,2,3,4-tetrahydroisoqinoline ring resulted in compounds having a high affinity 
and excellent selectivity for σ2 versus σ1 receptors, and a dramatic reduction in affinity for 
dopamine receptors [35]. As discussed in greater detail below, the conformationally-flexible 
benzamide analogs have proven to be an important class of σ2-selective compounds for the 
preparation of radiolabeled probes to image this receptor in vitro and in vivo. 
 
 
 
Fig. 3. The conformationally-flexible benzamide-based σ2 receptor ligands for in vitro 
studies of the σ2 receptor. A: YUN250 was a lead for generating the conformationally-
flexible benzamide analogues which are selective for σ2 receptors. The tritium labeled 
ligand, [3H]RHM-1 , has been used to conduct the receptor binding assay. B: Scatchard 
studies of σ2 receptors in EMT-6 mouse breast tumors and NMNU-induced rat breast 
tumors with [3H]RHM-1. This probe has high affinity to the σ2 receptors in the rodent breast 
tumors and is useful for in vitro binding studies. 
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4. In vitro binding and in vivo imaging studies of σ2 receptors 
The conformationally-flexible benzamide analogs have been used to develop the σ2 
radioligands for in vitro binding studies. The tritium labeled σ2 selective ligand, [3H]RHM-1, 
has been used to conduct Scatchard studies of σ2 receptors in tumors and normal tissues 
(Figure 3A)[37, 38]. The in vitro receptor binding studies indicate that [3H]RHM-1 binds 
with a high affinity to both EMT-6 mouse breast tumors (Kd=3.45 nM) and chemically-
induced rat breast tumors (Kd=4.66 nM). The σ2 receptor densities of both tumors are found 
to be high (Bmax =2290 fmol/mg of protein for EMT-6 mouse breast tumors and Bmax=2410 
fmol/mg of protein for N-methyl-N-nitrosourea (NMNU)-induced rat breast tumors) 
(Figure 3B). The pharmacologic profile of [3H]RHM-1 is in agreement with that of [3H]di-o-
tolylguanidine ([3H]DTG), a most commonly used radioligand for the σ2 receptor binding 
assay. These results indicate that [3H]RHM-1 is a useful radioligand for studying 2 
receptors in vitro. 
The high correlation between the density of σ2 receptors and the proliferative status of solid 
tumors indicates that σ2 selective radiotracers can be used for imaging the proliferative 
status of solid tumors with PET and SPECT. The conformationally-flexible benzamide 
analogs have been used for the development of PET radiotracers for imaging the σ2 receptor 
status of solid tumors. The first PET radiotracers prepared were [11C]1-4 (Figure 4A), which 
involves labeling the corresponding ortho-hydroxy group with [11C]methyl iodide [38]. 
MicroPET and tumor uptake studies were conducted with [11C]1-4; the most promising 
analog proved to be [11C]4. Although all four analogs had a high affinity for σ2 receptors, the 
optimal lipophilicity of [11C]4 was responsible for the high tumor uptake and suitable signal: 
normal tissue ratios for imaging. These data indicate that both receptor affinity and 
lipophilicity are important properties for successful receptor-based tumor imaging agents. 
MicroPET and MicroCT imaging studies in a murine solid breast tumor EMT-6 clearly show 
the potential of [11C]4 as a radiotracer for imaging the σ2 receptor status of breast tumors 
with PET. 
Although [11C]4 provides a clear image of breast tumors in microPET imaging studies, the 
short half life of carbon 11 (t1/2 = 20.4 min) is not ideal for the development of radiotracers 
which can be used in clinical PET imaging studies. The longer half-life of 18F (t1/2 =109.8 
min) compared to 11C places fewer time constraints on tracer synthesis, allows imaging 
studies to be conducted up to 2 h after injection of the radiotracers, and usually results in 
higher tumor: normal tissue ratios. A number of 18F-labeled radiotracers [18F]5-8 (Figure 4B) 
based on the conformationally-flexible benzamide analogs have been generated and 
evaluated in murine breast tumor models[39]. The strategy involved replacement of the 2-
methoxy group in the benzamide ring with a 2-fluoroethoxy group. The 2-fluoroethoxy- for 
methoxy-substitution is a common strategy used in the development of 18F-labeled 
radiotracers. Biodistribution studies in female Balb/c mice bearing EMT-6 tumor allografts 
demonstrated that all four 18F -labeled compounds had a high tumor uptake (2.5-3.7% ID/g) 
and acceptable tumor/normal tissue ratios at 1 and 2 h post-i.v. injection (Figure 4C). The 
moderate to high tumor/normal tissue ratios and the rapid clearance from the blood for 
[18F]5 and [18F]8 suggests that these radiotracers are likely the best candidates for imaging of 
solid tumors with PET. MicroPET imaging studies indicate that [18F]5 and [18F]8 are suitable 
probes for imaging the σ2 receptor status of solid tumors with PET (Figure 4D). Clinical 
studies of [18F]8 are currently in progress in the US. 
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Fig. 4. The synthetic schemes for generating conformationally-flexible benzamide-based PET 
radiotracers. A: A number of 11C-labeled radiotracers, [11C]1-4, are prepared by labeling the 
corresponding ortho-hydroxy group with [11C]methyl iodide. B: A number of 18F-labeled 
radiotracers, [18F]5-8, are generated by replacing of the 2-methoxy group in the benzamide 
ring with a 2-fluoroethoxy group. C: Biodistribution studies in female Balb/c mice bearing 
EMT-6 tumor allografts demonstrating that all four 18F -labeled compounds had a high 
tumor uptake (2.5-3.7% ID/g) and acceptable tumor/normal tissue ratios at 2 h post-i.v. 
injection. D: MicroPET imaging studies indicate that [18F]5 and [18F]8 are suitable probes for 
imaging the σ2 receptor status of solid tumors with PET.  
5. Confocal and two photon microscopy studies of σ2 receptors in tumor cells 
Since the σ2 receptor protein has not been cloned, current knowledge of this receptor is 
based predominantly on receptor binding studies with radiolabeled probes such as 
[3H]DTG. The function of the σ2 receptors has also been investigated by studying their 
effects on the biochemical and physiological properties of tumor cells. Several studies have 
shown that σ2 ligands induced cell death. The proposed mechanisms of cell death include 
caspase-independent apoptosis [40], lysosomal leakage [41], Ca2+ release [42, 43], oxidative 
stress [41], ceramide production [44] and autophagy [45]. However, the subcellular 
localizations where the σ2 ligands bind and function were not known. Using the fluorescent 
probes shown in Figure 2, Zeng and colleagues[33, 34] recently conducted a series of 
confocal and two photon microscopy studies that have provided the information regarding 
the localization of σ2 receptors in breast tumor cells. 
MDA-MB-435 cells were incubated with 30 nM SW120 and each of the five subcellular 
organelle markers: the mitochondria tracker, MitoTracker Red CMXRos (20 nM ), the 
endoplasmic reticulum tracker, ER-TrackerTM Red (500 nM), the lysosome tracker, 
LysoTracker Red DND-99 (50 nM), the nuclear marker, DAPI (300 nM), or the plasma 
membrane tracker, FM 4-64FX (5 g/mL). The results showed that SW120 partially co-
localized with MitoTracker, ER-Tracker, LysoTracker and the plasma membrane tracker, 
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suggesting that σ2 receptors may localize in mitochondria, endoplasmic reticulum, 
lysosomes and the plasma membrane (Figure 5). The data also showed that SW120 did not 
co-localize with the nuclear marker, DAPI, suggesting that either the σ2 receptor does not 
exist in the nucleus or SW120 does not enter the nucleus. The similar results were obtained 
for the other σ2 fluorescent probes (SW116, K05-138 and SW107)[33, 34]. 
 
 
Fig. 5. Determination of the intracellular distribution of SW120 in MDA-MB-435 cells with 
and without MitoTracker (A), ER-Tracker (B), LysoTracker (C), a nuclear marker, DAPI (D), 
or a membrane tracker, FM4-64FX (E), using confocal microscopy. MDA-MB-435 cells were 
incubated with 30 nM SW120 and either 20 nM MitoTracker, 500 nM ER-Tracker, 50 nM 
LysoTracker, or 300 nM DAPI. After incubating for 2 h at 37C, live cells were imaged by 
confocal microscopy. MDA-MB-435 cells were also incubated with 50 nM SW120 and 5 
g/mL of the membrane tracker, FM4-64FX, for 15 min at 0C. The live cells were imaged 
by confocal microscopy. Scale bar = 10 m. 
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The kinetic studies of internalization of σ2 fluorescent probes in MDA-MB-435 cells were 
conducted using confocal microscopy[33, 34]. σ2 fluorescent probes enter tumor cells 
rapidly. For example, K05-138 and SW120 reach 50% of the maximal fluorescent intensity 
(T1/2) in 16 seconds and 11 minutes, respectively (Figure 6A). The internalization of SW120 
can be blocked by the σ2 selective ligands, SW43 and siramesine, by 52% and 44%, 
respectively (Figure 6B). This internalization can not be blocked by the σ1 selective ligand, 
(+)-pentazocine. The data suggest that the internalization of the σ2 selective ligand is 
partially mediated by σ2 receptor. In order to study whether the internalization of the σ2 
ligand is mediated by endocytosis, Zeng et al examined the effect of phenylarsine oxide 
(PAO), a well-characterized endocytosis inhibitor [46], on the internalization of SW120. 
MDA-MB-435 cells were pretreated with 5 or 10 M PAO for 30 min, and then treated with 
10 nM SW120 in the absence or presence of PAO for an additional 30 min. Flow cytometric 
analysis (Figure 6C) showed that 10 M PAO significantly blocked internalization of SW120 
by 30%. These data demonstrate that 30% of the 2 receptor ligand was internalized by an 
endocytosis-mediated mechanism, while the remaining 70 % was internalized by other 
mechanisms such as passive diffusion. The rapid internalization of σ2 receptors via 
endocytosis suggests that σ2 selective ligands may potentially serve as receptor-mediated 
probes for delivering cytotoxic agents to solid tumors. 
The two photon and confocal microscopy studies conducted by Zeng et al.[33, 34] have 
provided useful information for the interpretation of studies demonstrating that σ2 receptor 
ligands may have a role as cancer chemotherapeutic agents. Mitochondria are a key 
organelle to regulate the intrinsic apoptotic pathway. Apoptotic signals such as UV 
irradiation or treatment with chemotherapeutic agents cause the release of cytochrome C 
from the mitochondria and the subsequent activation of caspase-3 leading to an apoptotic 
cell death[47]. The subcellular localization of σ2 ligands in mitochondria is consistent with 
the previous studies that 2 ligands trigger apoptosis in tumor cells by acting on 
mitochondria [48]. The data are also consistent with our observation by transmission 
electron microscopy that the 2 ligand siramesine induces distortion of mitochondria 
(unpublished data). The endoplasmic reticulum (ER) serves as a dynamic Ca2+ storage pool 
[49]. σ2 selective ligands have been reported to induce transient Ca2+ release from the ER, 
which may be responsible for σ2 ligand-induced cell death [42]. The presence of the σ2 
fluorescent probes in the ER is consistent with these results. Additional research will be 
required to determine how σ2 receptors regulate the Ca2+ release channels in the ER. 
Lysosomal proteases, such as cathepsins, calpains and granzymes, have been reported to 
contribute to apoptosis [50]. Under physiological conditions, these proteases are found 
within the lysosomes but are released into the cytoplasm upon exposure to cell damaging 
agents, thereby triggering a cascade of intracellular events leading to cell death. The σ2 
selective ligand siramesine has been reported to cause lysosomal leakage and induce cell 
death by caspase-independent mechanisms [41, 45]. The localization of fluorescent σ2 
receptor probes in the lysosomes is consistent with the hypothesis that siramesine induces 
cell death partially by targeting lysosomes to cause lysosomal damage, the release of 
proteases, and eventually cell death. Evidence has also been reported that σ2 receptors exist 
in lipid rafts which are mainly found in the plasma membrane [51]. Lipid rafts play an 
important role in the signaling associated with a variety of cellular events including 
adhesion, motility, and membrane trafficking [52, 53]. The observation that σ2 fluorescent 
ligands are co-localized with cytoplasmic membrane markers, and undergo receptor 
mediated endocytosis, is consistent with their localization in lipid rafts. How the σ2 receptor 
is involved in lipid raft function deserves further investigation. 
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Fig. 6. Characterization of σ2 fluorescent probes. A: The internalization kinetics of SW120 in 
MDA-MB-435 cells by confocal microscopy studies show that SW120 enters tumor cells 
rapidly. B: The internalization of SW120 in MDA-MB-435 cells are partially blocked by σ2 
selective ligands, SW43 and siramesine, but not by a σ1 selective ligand, (+)-pentazocine. C: 
The inhibition of SW120 internalization by phenylarsine oxide (PAO). MDA-MB-435 cells 
were preincubated with 5 or 10 M PAO for 30 min at 37C, and then incubated with 10 nM 
SW120 for an additional 30 min. The cells were analyzed by flow cytometry. The 
internalization of SW120 was significantly reduced by 10 μM PAO (* P < 0.05). 
The σ2 receptor has been validated as a proliferation marker in cell culture and in solid 
tumors. Therefore it is possible that σ2 fluorescent probes could preferentially label 
proliferating cells versus non-proliferating cells and serve as agents to image cell 
proliferation in vivo. This hypothesis was tested in nude mice implanted with murine 
mammary adenocarcinoma 66 cells and BALB/C mice implanted with mouse mammary 
carcinoma cell line EMT6[34]. The mice were treated with SW120 (50 g in 100 L PBS) for 
one hour. The peripheral blood mononuclear cells (PBMC), which are commonly used as 
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controls for non-proliferative cells, and tumor cells were prepared. These cells were 
analyzed by flow cytometry for SW120 uptake and for Ki67 expression, a commonly-used 
proliferation marker. Our data showed that PBMC were Ki67 negative, whereas a large 
portion of the tumor cells were Ki-67 positive (Figure 7). The data also showed that PBMC 
were not labeled by SW120, whereas a portion of the tumor cells were labeled with SW120. 
The trend of the positive correlation between Ki67 expression and SW120 labeling implies 
that the fluorescent may possess in vivo selectivity toward proliferating cells versus non-
proliferative cells. These data suggest that σ2 fluorescent probes could be used as imaging 
agents for monitoring cell proliferation in mice. The data also suggest that σ2 selective 
ligands hold a potential to serve as therapeutic agents to selectively target tumor cells in 
vivo. 
 
 
Fig. 7. Ki67 expression and SW120 fluorescent intensity in solid mouse breast tumors and 
peripheral blood mononuclear cells (PBMC) of mice by flow cytometric analysis. The female 
nude mice were implanted with murine mammary adenocarcinoma 66 cells. BALB/C mice 
were implanted with mouse mammary carcinoma cell line EMT6. The mice were i.v. 
injected with SW120 (50 µg/ mouse) and tissues harvested after 1 hour. The 66 cells and 
EMT6 cells were dissociated from the solid tumors. PBMC were prepared from the blood of 
mice. The cells were analyzed for the fluorescent intensity of SW120 and the Ki67 expression 
determined by Ki67 immunostaining using a flow cytometer. The data indicate the trend of 
the positive correlation between Ki67 expression and SW120 labeling.  
6. Conclusions 
The 2 receptor continues to be an important molecular target in the field of tumor biology. 
The high expression of this receptor in proliferating versus quiescent breast tumors indicates 
that the 2 receptor is an important clinical biomarker for determining the proliferative 
status of solid tumors using the functional imaging techniques PET and SPECT. The 2 
receptor fluorescent probes are useful to study the subcellular localization and the function 
of 2 receptors using confocal and two photon microscopy techniques, and may be used to 
image tumor proliferation in mice using optical imaging techniques. The full utility of the 2 
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receptor in the diagnosis and prediction of therapeutic response will rely on the cloning of 
the 2 receptor and elucidation of its functional role in normal and tumor cell biology. 
Note: While this article is accepted, a paper from our group is published in Nature Communication[54]. 
In this paper we have identified progesterone receptor membrane component 1(PGRMC1) as the 
putative 2 receptor. This finding will greatly facilitate investigations of the functions of the 2 receptor 
in normal and tumor cells.  
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